Uncategorized

Authors and Affiliations: Patrícia Correia1, Paula Araújo1, Joana Marto2, Helena Ribeiro2, Nuno Mateus1, Victor de Freitas1, Joana Oliveira1 & Iva Fernandes1 1REQUIMTE/LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, s/n, 4169-007 Porto, Portugal. 2Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Avenida Prof. Gama…

Researchers from the Molecular Oncology and Viral Pathology Group (GOMPV) at the Research Center of IPO-Porto (CI-IPOP), in collaboration with researchers from Instituto de Investigação e Inovação em Saúde (i3S), established a 3D in vitro model of castration-resistant prostate cancer, applicable for identifying extracellular vesicle (EV)-derived microRNAs predictive of enzalutamide (ENZ) resistance development. Despite the…

Study shows that diosgenin, a phytosteroid sapogenin, suppresses viability and promotes apoptosis of human prostate cancer cells with effects enhanced by the activation of the G protein-coupled estrogen receptor activation. Authors and Affiliations: Marília I. Figueira1, Ricardo Marques2, Henrique J. Cardoso1, Lara R. S. Fonseca1, Ana P. Duarte1, Samuel Silvestre1 and Sílvia Socorro1 1CICS-UBI—Health Sciences…

The study “Combination of gold nanoparticles with near-infrared light as an alternative approach for melanoma management” investigated the combination of gold nanoparticles with near-infrared laser irradiation as a promising therapeutic strategy for melanoma treatment. The different assays conducted demonstrated nanoparticles or the laser alone did not cause significant cytotoxic effects. In contrast, the combined therapy…

Hepatocellular carcinoma (HCC) is one of the main causes of cancer death worldwide. Thus, the main objective of this work was to develop a new targeted lipid-polymer hybrid nanosystem that could allow the simultaneous transport of different therapeutic agents, namely antitumor drugs and nucleic acids, and their specific delivery in HCC cells. This formulation has…

Researchers from the Molecular Oncology and Viral Pathology Group (GOMPV) at the IPO-Porto Research Center (CI-IPOP), in collaboration with researchers from the Departments of Medical Oncology, Onco-Hematology, and Occupational Health at IPO-Porto, conducted a study on the immune response of cancer patients to the SARS-CoV-2 vaccination booster. The project focused on studying humoral immunity over…

With the approval of the first Immune-Checkpoint Inhibitor (ICI), a new category of side effects has emerged – immune-related adverse events. ICI-related pneumonitis is a rare, but potentially fatal side effect, with an incidence of 3–10% in different trials involving ICI, with greater incidence in patients with non-small cell lung cancer (NSCLC). This is the…

Authors and Affiliations:Rita F. Oliveira 1,2, Ana I. Oliveira 1, Agostinho Cruz 1, Oscar Ribeiro 2, Vera Afreixo 3 and Francisco Pimentel 4 1 REQUIMTE/LAQV, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal 2 Center for Health Technology and Services Research at the Associate Laboratory RISE—Health Research Network (CINTESIS@RISE),…

Authors and Affiliations: Diana Luísa Almeida-Nunes 1,2,3, João P. N. Silva 4, Mariana Nunes 3,5, Patrícia M. A. Silva 1,4,6, Ricardo Silvestre 7,8, Ricardo Jorge Dinis-Oliveira 1,6,9,10, Hassan Bousbaa 4 and Sara Ricardo 1,2,3,4, 1 Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal. 2 UCIBIO—Applied Molecular Biosciences Unit,…

Venous thromboembolism (VTE) affects up to 20% of cancer patients, presenting a risk four to seven times higher than that of the general population. This elevated risk is attributed to factors related to the patient, the tumour, and treatments. When deciding on primary thromboprophylaxis, these factors, along with the potential for bleeding and the impact…